Drugs / 5-Hydroxytryptophan
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05895747 | Sep 2023 → Jun 2026 overdue | major depressive disorder | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT05030129 | Oct 2021 → Jan 2023 | fragile X syndrome | Elizabeth Berry-Kravis | Completed | No outcome recorded |
| Phase 2 | NCT00328913 | Mar → Jul 2006 | obesity disorder | TNO | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02356107 | Apr 2015 → Aug 2016 | major depressive disorder | Perry Renshaw | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04395183 Comparator | Mar 2021 → Aug 2023 | major depressive disorder | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT04160910 Comparator | Feb 2021 → Jun 2026 overdue | allergic asthma | Indiana University | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04520178 Comparator | Jul 2020 → Jun 2026 overdue | spinal cord injury | University of Alberta | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02922725 Comparator | Nov 2016 → May 2020 | major depressive disorder | Brent Michael Kious, MD, PhD | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5 hydroxytryptophan | “The investigators hypothesize that the administration of two widely available, naturally occurring dietary supplements, 5 hydroxytryptophan and creatine monohydrate, will...” NCT02356107 ↗ |
| Known as | 5-HTP | “The investigators propose to determine if 8 weeks of dietary augmentation with oral 5g creatine monohydrate daily and 100 mg of 5-hydroxytryptophan (5-HTP) twice daily reduces...” NCT02922725 ↗1“Period 3: 5-hydroxytryptophan (5-HTP) 100 mg three times per day for 4 weeks” NCT05030129 ↗ |
| Modality | Other / unclassified | “two widely available, naturally occurring dietary supplements” NCT02356107 ↗ |
| Route | Oral | “oral 5 g creatine daily and 100 mg 5-HTP twice daily” NCT02356107 ↗ |